Serum calprotectin levels correlate with biochemical and histological markers of disease activity in TNBS colitis

Cellular Immunology

Volumn 282, Issue 1, 2013, Pages 66-70

  Cury, Didia Bismara ^a,b   Mizsputen, Sender Jankiel ^a   Versolato, Clara ^a   Miiji, Luciana Odashiro ^a   Pereira, Edson ^a,b   Delboni, Maria Aparecida ^a   Schor, Nestor ^a   Moss, Alan C ^b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

C reactive protein; Inflammatory marker; Mucosal scores; Serum calprotectin; TNBS

Indexed keywords

C REACTIVE PROTEIN; CALGRANULIN; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLITIS; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; LOOSE FECES; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; WEIGHT REDUCTION;

EID: 84877887426     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2013.04.004     Document Type: Article

References (34)

1. Froslie K.F., Jahnsen J., Moum B.A., Vatn M.H. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology [Multicenter Study Research Support, Non-U.S. Gov't] 2007 Aug, 133(2):412-422.
2. Baert F., Moortgat L., Van Assche G., Caenepeel P., Vergauwe P., De Vos M., et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology [Multicenter Study Research Support, Non-U.S. Gov't] 2010 Feb, 138(2):463-468. quiz e10-e11.
3. Schnitzler F., Fidder H., Ferrante M., Noman M., Arijs I., Van Assche G., et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm. Bowel Dis. [Research Support, Non-U.S. Gov't] 2009 Sep, 15(9):1295-1301.
4. Loftus E.V. Clinical perspectives in Crohn's disease. Objective measures of disease activity: alternatives to symptom indices. Rev. Gastroenterol. Disord. [Review] 2007, 7(Suppl. 2):S8-S16.
5. Friedrich C., Fajfar A., Pawlik M., Hoffstetter P., Rennert J., Agha A., et al. Magnetic resonance enterography with and without biphasic contrast agent enema compared to conventional ileocolonoscopy in patients with Crohn's disease. Inflamm. Bowel Dis. 2012 Jan 9, 1842-1848.
6. Girlich C., Schacherer D., Jung E.M., Klebl F., Huber E. Comparison between quantitative assessment of bowel wall vascularization by contrast-enhanced ultrasound and results of histopathological scoring in ulcerative colitis. Int. J. Colorectal Dis. [Clinical Trial Comparative Study] 2012 Feb, 27(2):193-198.
7. Koulaouzidis A., Douglas S., Plevris J.N. Lewis score correlates more closely with fecal calprotectin than capsule endoscopy Crohn's disease activity index. Dig. Dis. Sci. 2012 Apr, 57(4):987-993.
8. Feuerbach S. MRI enterography: the future of small bowel diagnostics?. Dig. Dis. 2010, 28(3):433-438.
9. Ordas I, Rimola J, Rodriguez S, Gallego M, Ricart E, Panes J. Imaging of the colon in inflammatory bowel disease: ready for prime time? Curr. Drug Targets (2012 May 28) 1252-1260.
10. Vermeire S., Van Assche G., Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm. Bowel Dis. [Review] 2004 Sep, 10(5):661-665.
11. Schoepfer A.M., Vavricka S., Zahnd-Straumann N., Straumann A., Beglinger C. Monitoring inflammatory bowel disease activity: clinical activity is judged to be more relevant than endoscopic severity or biomarkers. J. Crohns Colitis [Research Support, Non-U.S. Gov't] 2012 May, 6(4):412-418.
12. Card T. Commentary: is CRP ready for use to indicate response or remission with infliximab in Crohn's?. Aliment Pharmacol. Ther. [Comment Research Support, Non-U.S. Gov't] 2012 Apr, 35(8):960-961. [discussion 1-2].
13. Denis M.A., Reenaers C., Fontaine F., Belaiche J., Louis E. Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn's disease with normal C-reactive protein serum level. Inflamm. Bowel Dis. [Research Support, Non-U.S. Gov't] 2007 Sep, 13(9):1100-1105.
14. Vermeire S., Van Assche G., Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys?. Gut [Review] 2006 Mar, 55(3):426-431.
15. Fagerberg U.L., Loof L., Lindholm J., Hansson L.O., Finkel Y. Fecal calprotectin: a quantitative marker of colonic inflammation in children with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. [Research Support, Non-U.S. Gov't Validation Studies] 2007 Oct, 45(4):414-420.
16. Sipponen T., Karkkainen P., Savilahti E., Kolho K.L., Nuutinen H., Turunen U., et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Aliment Pharmacol. Ther. [Research Support, Non-U.S. Gov't] 2008 Nov 15, 28(10):1221-1229.
17. Lewis J.D. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology [Research Support, N.I.H., Extramural Review] 2011 May, 140(6):1817-1826.
18. Ricanek P., Brackmann S., Perminow G., Lyckander L.G., Sponheim J., Holme O., et al. Evaluation of disease activity in IBD at the time of diagnosis by the use of clinical, biochemical, and fecal markers. Scand. J. Gastroenterol. [Research Support, Non-U.S. Gov't] 2011 Sep, 46(9):1081-1091.
19. Foell D., Wittkowski H., Roth J. Monitoring disease activity by stool analyses: from occult blood to molecular markers of intestinal inflammation and damage. Gut [Research Support, Non-U.S. Gov't Review] 2009 Jun, 58(6):859-868.
20. Morris G.P., Beck P.L., Herridge M.S., Depew W.T., Szewczuk M.R., Wallace J.L. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology [Comparative Study Research Support, Non-U.S. Gov't] 1989 Mar, 96(3):795-803.
21. Edgeworth J., Freemont P., Hogg N. Ionomycin-regulated phosphorylation of the myeloid calcium-binding protein p14. Nature 1989 Nov 9, 342(6246):189-192.
22. Nikolaus S., Bauditz J., Gionchetti P., Witt C., Lochs H., Schreiber S. Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin 10 during intestinal inflammation. Gut 1998 Apr, 42(4):470-476. (PubMed PMID: 9616306. Pubmed Central PMCID: 1727082).
23. Hanai H., Takeuchi K., Iida T., Kashiwagi N., Saniabadi A.R., Matsushita I., et al. Relationship between fecal calprotectin, intestinal inflammation, and peripheral blood neutrophils in patients with active ulcerative colitis. Dig. Dis. Sci. 2004 Sep, 49(9):1438-1443.
24. Andres Cerezo L., Mann H., Pecha O., Plestilova L., Pavelka K., Vencovsky J., et al. Decreases in serum levels of S100A8/9 (calprotectin) correlate with improvements in total swollen joint count in patients with recent-onset rheumatoid arthritis. Arthritis Res. Ther. 2011, 13(4):R122. [PubMed PMID: 21791097. Pubmed Central PMCID: 3239361].
25. Tibble J.A., Sigthorsson G., Bridger S., Fagerhol M.K., Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology [Comparative Study] 2000 Jul, 119(1):15-22.
26. Schoepfer A.M., Beglinger C., Straumann A., Trummler M., Vavricka S.R., Bruegger L.E., et al. Fecal calprotectin correlates more closely with the simple endoscopic score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am. J. Gastroenterol. [Research Support, Non-U.S. Gov't] 2010 Jan, 105(1):162-169.
27. Peyrin-Biroulet L., Ferrante M., Magro F., Campbell S., Franchimont D., Fidder H., et al. Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease. J. Crohns Colitis [Consensus, Development Conference] 2011 Oct, 5(5):477-483.
28. Strober W., Fuss I.J. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology [Review] 2011 May, 140(6):1756-1767.
29. Alex P., Zachos N.C., Nguyen T., Gonzales L., Chen T.E., Conklin L.S., et al. Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis. Inflamm. Bowel Dis. [Comparative Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't] 2009 Mar, 15(3):341-352.
30. Gustot T., Lemmers A., Louis E., Nicaise C., Quertinmont E., Belaiche J., et al. Profile of soluble cytokine receptors in Crohn's disease. Gut [Research Support, Non-U.S. Gov't] 2005 Apr, 54(4):488-495.
31. Hyams J.S., Treem W.R., Eddy E., Wyzga N., Moore R.E. Tumor necrosis factor-alpha is not elevated in children with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 1991 Feb, 12(2):233-236.
32. Schoepfer A.M., Beglinger C., Straumann A., Safroneeva E., Romero Y., Armstrong D., et al. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger index, C-reactive protein, platelets, hemoglobin, and blood leukocytes. Inflamm. Bowel Dis. 2013 Feb, 19(2):332-341.
33. Thalmaier D., Dambacher J., Seiderer J., Konrad A., Schachinger V., Pfennig S., et al. The +1059G/C polymorphism in the C-reactive protein (CRP) gene is associated with involvement of the terminal ileum and decreased serum CRP levels in patients with Crohn's disease. Aliment Pharmacol. Ther. [Research Support, Non-U.S. Gov't] 2006 Oct 1, 24(7):1105-1115.
34. Souza M.M., Nascimento J.E., Dock-Nascimento D.B. Effects of budesonide and probiotics enemas on the systemic inflammatory response of rats with experimental colitis. Acta Cir. Bras. 2007 Mar-Apr, 22(Suppl 1):40-45.